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BACKGROUND AND PURPOSE
Myocardial cAMP elevation confers cardioprotection against ischaemia/reperfusion (I/R) injury. cAMP activates two independent
signalling pathways, PKA and Epac. This study investigated the cardiac effects of activating PKA and/or Epac and their
involvement in cardioprotection against I/R.
EXPERIMENTAL APPROACH
Hearts frommale rats were used either for determination of PKA and PKC activation or perfused in the Langendorff mode for either
cardiomyocyte isolation or used to monitor functional activity at basal levels and after 30 min global ischaemia and 2 h
reperfusion. Functional recovery and myocardial injury during reperfusion (LDH release and infarct size) were evaluated.
Activation of PKA and/or Epac in perfused hearts was induced using cell permeable cAMP analogues in the presence or absence of
inhibitors of PKA, Epac and PKC. H9C2 cells and cardiomyocytes were used to assess activation of Epac and effect on Ca2+
transients.
KEY RESULTS
Selective activation of either PKA or Epac was found to trigger a positive inotropic effect, which was considerably enhanced when
both pathways were simultaneously activated. Only combined activation of PKA and Epac induced marked cardioprotection
against I/R injury. This was accompanied by PKCε activation and repressed by inhibitors of PKA, Epac or PKC.
CONCLUSION AND IMPLICATIONS
Simultaneous activation of both PKA and Epac induces an additive inotropic effect and confers optimal and marked
cardioprotection against I/R injury. The latter effect is mediated by PKCε activation. This work has introduced a new therapeutic
approach and targets to protect the heart against cardiac insults.
Abbreviations
CaMKII, Ca2+/calmodulin-dependent protein kinase II; CPT, 8-(4-chlorophenylthio)-20-O-methyladenosine-30,50-cyclic
monophosphate, acetoxymethyl ester (8-pCPT-20-O-Me-cAMP-AM); ESI-09, 3-[5-(tert.-butyl)isoxazol-3-yl]-2-
[2-(3-chlorophenyl)hydrazono]-3-oxopropanenitrile; HR, heart rate; I/R, ischaemia/reperfusion; IP, ischaemic
preconditioning; KH, Krebs–Henseleit buffer; LVDP, left ventricular developed pressure; MPTP, mitochondria permeability
transition pore; PKI, PKA inhibitor 14–22 amide; RPP, rate-pressure product; RyR2, ryanodine receptor; 6-Bnz,
N6-benzoyladenosine-30,50-cyclic monophosphate, acetoxymethyl ester (6-Bnz-cAMP-AM); 8-Br, 8-bromoadenosine-
30,50-cyclic monophosphate, acetoxymethyl ester (8-Br-cAMP-AM); +dP/dt, time derivative of pressure measured during
contraction; -dP/dt, time derivative of pressure measured during relaxation
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Introduction
Cardiac ischaemia/reperfusion (I/R) injury can occur during
coronary angioplasty, cardiac surgery and heart transplanta-
tion (Depre and Taegtmeyer, 2000) contributing to morbidity
andmortality (Eltzschig and Eckle, 2011). This injury is medi-
ated by the opening of the mitochondria permeability transi-
tion pore (MPTP), which can be triggered by Ca2+ overload
(Halestrap et al., 2004) and ROS (Honda et al., 2005; Halestrap
and Pasdois, 2009). We and others have provided evidence
showing that the cAMP signal transduction pathways are in-
volved in mediating a number of cardioprotective effects
(Lochner et al., 1999; Khaliulin et al., 2010; Khaliulin et al.,
2014). Our work has also identiﬁed PKC as a critical compo-
nent of cAMP/PKA-induced cardioprotection (Khaliulin
et al., 2007; Khaliulin et al., 2010). A major problem associ-
ated with targeting the cAMP/PKA pathway is the fact that
this treatment has relied on stimulation of β-adrenoceptors,
which may be impaired in chronic heart failure due to
hyperstimulation of β-adrenoceptors, mediated via the
sympathetic nervous system (Cannavo et al., 2013;
Lymperopoulos et al., 2013). Therefore, if the protective
cAMP-related signalling mechanisms can be activated with-
out stimulation of β-adrenoceptors, this would give a signiﬁ-
cant therapeutic advantage. Although most of the biological
effects of cAMP on the heart have been assigned to PKA (Bers,
2007), cAMP also activates Epac (a guanine nucleotide
exchange protein directly activated by cAMP) (de Rooij
et al., 1998). The cAMP/Epac pathway is independent of and
parallel to the cAMP/PKA signalling pathway (Pereira et al.,
2012; Okumura et al., 2014). Therefore, availability of cell-
permeable cAMP analogues allowing selective activation of
either PKA or Epac represents a valuable tool to identify the
involvement and the contribution of these cAMP sensors in
cardioprotection (Dudley et al., 2014). cAMP analogues have
been successfully used in work involving vascular smooth
muscle cell proliferation where both PKA and Epac were
found to act synergistically at inhibiting proliferation (Hewer
et al., 2011; Kimura et al., 2014). In this study, we investigated
the cardioprotective efﬁcacy of cAMP/PKA and cAMP/Epac
signalling pathways using cell permeable cAMP analogues
that are selective activators of either PKA or Epac or both
and assessed the involvement of PKC in the cAMP-induced
cardioprotection.
Methods
Animals
All animal care and experimental procedures conformed to the
Animals (Scientiﬁc Procedures) Act, 1986 of the UK Parliament,
Directive 2010/63/EU of the European Parliament and the
Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No.
85–23, revised 1996). Ethical approval was granted by the
Animal Welfare and Ethics Review Board of the University of
Bristol, UK. Animal studies are reported in compliance with
the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and
Lilley, 2015).
The experiments were performed using 2-month-oldmale
Wistar rats (250–260 g) supplied by Charles River Laborato-
ries (Oxford, UK). Prior to experiments, the animals were
housed at the University of Bristol Animal Services Unit for
2–4 days at 23 ± 1°C, with a relative humidity of 60–70%
and a light/dark cycle of 12 h with free access to water and
standard rat chow. The rats were kept in standard cages, two
to three animals per cage, with aspen bedding. The rats were
killed by stunning and cervical dislocation and used for
experiments on isolated heart and cardiomyocytes. Freshly
isolated rat cardiomyocytes and the H9C2 cell line were
used for validation and optimization of PKA and Epac
activation induced by the cell-permeable cAMP
analogues: 8-bromoadenosine-30,50-cyclic monophosphate,
acetoxymethyl ester (8-Br); N6-benzoyladenosine-30,50-cy-
clic monophosphate, acetoxymethyl ester (6-Bnz) and
8-(4-chlorophenylthio)-20-O-methyladenosine-30,50-cyclic
monophosphate, acetoxymethyl ester (CPT).
H9C2 cell culture
Rat heart cardiomyoblasts H9C2 were incubated in plates
(150 000 cells·mL1) at 37°C in DMEM (Invitrogen Gibco,
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Paisley, UK) with L-glutamine (1%), penicillin (100 U·mL1)
and streptomycin (100 U·mL1) for 7 h with either 5 μM
8-Br, 5 μM8-Br + 1 μMESI-09 or 10 μMCPT. RNA of these cells
was extracted, transcribed to cDNA, and expression of the
gene c-fos, used as an indicator of Epac activation (Glas
et al., 2016), was assessed by qRT-PCR. The average c-fos
expression of three experiments was calculated for each
group of cells. The gene expression was calculated as fold
change relative to the control. The level of gene expression
in the control groups was set as 1.
H9C2 cells were selected because they are rat heart
cardiomyoblasts and therefore represent a rat cardiomyocyte
precursor cell-type. Moreover, H9C2 cells in culture are very
robust and allow experiments of prolonged duration to be
conducted. In particular, this allowed us to perform the deter-
mination of c-fos expression in cells treated with 8-Br, CPT
and the Epac inhibitor, ESI-09.
Assessment of PKA and PKC activation in
isolated rat heart
PKA activation was assessed by measuring phosphorylation
of VASP with phospho-VASP (Ser157) antibody (rabbit; from
Cell Signalling Technology, Inc., NEB, Hitchin, UK; diluted
1:1000) byWestern blots and using an ELISA-based PKA kinase
activity assay.
For detection of VASP phosphorylation, proteins were ex-
tracted from powdered frozen ventricular cardiac tissue from
rat hearts that were perfused in the Langendorff mode with
different drugs according to the protocols described below.
The protein extraction buffer contained (mM) the following:
300 sucrose, 10 Tris–HCl, 1 EGTA, 2 sodium pyrophosphate,
2 sodium ﬂuoride, 2 β-glycerophosphate, complete protease
inhibitor cocktail (Roche Diagnostics, Burgess Hill, UK) and
phosphatase inhibitor cocktail 3 (Sigma, Gillingham, UK).
Separation of the cytosol and membrane fractions of the
heart samples was carried out as described earlier (Clarke
et al., 2008). In brief, cell debris were removed from protein
extraction buffer by centrifugation at 2000 × g for 1.5 min.
The supernatant was centrifuged at 200 000 × g for 1 h,
and the resulting supernatant was taken as the cytosolic
fraction. The pellet (membrane fraction) was resuspended
in the protein extraction buffer. After diluting the samples
(1:1 v·v1) with the SDS sample buffer containing at ﬁnal
concentration: 50 mM Tris–HCl, 2 mM EDTA, 12% glycerol
and 10% SDS, protein concentration was adjusted to
2 mg·mL1 using BCA Protein Assay (Thermo Fisher Scien-
tiﬁc, Loughborough, UK). Then, 2-mercaptoethanol and
bromophenol blue were added at ﬁnal concentrations of 5%
and 0.01%, accordingly. All the procedures of the protein
separation were carried out at 4°C. Lysate from forskolin-
stimulated rat smooth muscle cells was used as a positive
control for evaluation of PKA activation by VASP phosphory-
lation. Protein loading was assessed with anti-GAPDH
antibody (Cell Signalling Technology, Inc., NEB, Hitchin,
UK; diluted 1:8000).
An additional method was also employed to determine
PKA activation using an ELISA-based PKA kinase activity assay
kit (ab139435, Abcam, Cambridge, UK). This kit was used
for measuring the PKA activity in the lysates of frozen
ventricular cardiac tissue. The frozen heart powders were
mixed with the lysis buffer containing (mM) the following:
20 MOPS, 50 β-glycerolphosphate, 5 EGTA, 2 EDTA, 1%
NP40, complete protease inhibitor cocktail (Roche Diagnos-
tics, West Sussex, UK) and phosphatase inhibitor cocktail 3
(Sigma, Gillingham, UK). The samples were centrifuged at
2000 × g for 5 min at 4°C to remove the cell debris. Protein
concentration was adjusted to 4 mg·mL1 using BCA
protein assay. About 2 μg of protein of each sample were
assayed according to the manufacturer’s instructions but
without the addition of 0.5 mM of ATP to the heart samples
(Supplementary Information Fig. S3).
Activation of PKCε and PKCδ was assessed by transloca-
tion of these PKC isoforms from the cytosol to membrane
fraction (Mochly-Rosen et al., 1990). Samples (20 μg per well)
containing the cytosol and membrane fractions were sepa-
rated by 10% SDS-PAGE and subjected to Western blotting
with anti-PKCε; and anti-PKCδ primary antibody (rabbit;
from Cell Signalling Technology, Inc., NEB, Hitchin, UK; di-
luted 1:1000). Each blot contained samples of both cytosol
and membrane fractions from the hearts of control and
8-Br-treated hearts to allow direct comparison (Figure 3A–B).
Membrane-to-cytosol fraction ratio of the optical density
was used to evaluate activation of PKCε and PKCδ. Equal
protein loading was conﬁrmed by staining of the PVDF
membranes with Ponceau-S stain for 2 min at room
temperature followed bywashwith tapwater (Supplementary
Information Fig. S4).
All blots were scanned with an HP scanner, and quantiﬁ-
cation of band intensity was performed using AlphaEase
v5.5 software followed by background subtraction.
Cardiomyocyte isolation and superfusion
The aim of these experiments was to establish whether the
strong inotropic response produced by 8-Br, which activates
both PKA and Epac, is mediated by an increase in intracellular
Ca2+ transients that is comparable with isoprenaline, which
we have previously found to induce a strong cardioprotective
effect (Khaliulin et al., 2014). We used an established model
of monitoring Ca2+ transient in isolated adult rat
cardiomyocytes. Rat cardiomyocytes were isolated using col-
lagenase Type I (Worthington Biochemical Corporation,
Lakewood, New Jersey, USA) and protease as described previ-
ously (Williams et al., 2001). Cells were loaded with Fura-2-
AM (5 μM; Biotium, Cambridge, UK), and Ca2+ transients
were recorded at the excitation/emission of 415/510 nm
using a photomultiplier as described elsewhere (Littlejohns
et al., 2014). Brieﬂy, cardiomyocytes were superfused at a rate
of 0.4 mL·min1 (32–33°C) with HEPES buffer solution
consisting of (mM) as follows: 137 NaCl, 5 KCl, 1.2
MgSO4·7H2O, 1.2 NaH2PO4·2H2O, 20 HEPES, 15 D-glucose
anhydrous and 2 CaCl2 (pH 7.4). The stimulation voltage
was set at just above the threshold required for the cell to
beat. The photomultiplier was connected to Felix 32 Analysis
v1.2 software (Photon Technology International, USA). After
a 20 min equilibration period, cells were superfused with a
HEPES buffer containing either 10 nM isoprenaline or 5 μM
8-Br for 5 min followed by 5 min washout.
Langendorff perfusion of rat isolated hearts
Rats were killed as described above, hearts (~0.75 g) were
rapidly removed into ice-cold Krebs–Henseleit buffer (KH)
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containing (mM) the following: 118 NaCl, 25 NaHCO3, 4.8
KCl, 1.2 KH2PO4, 1.2 MgSO4, 11 glucose and 1.2 CaCl2,
gassed with 95% O2–5% CO2 at 37°C (pH 7.4) and perfused
in Langendorff mode as described previously (Khaliulin
et al., 2011). All hearts were allowed an equilibration period
of at least 25 min before any additional treatment was given.
Data acquisition and analysis used a PowerLab System
(ADInstruments Ltd, Oxford, UK). Left ventricular developed
pressure (LVDP) was calculated as the difference between left
ventricular systolic pressure and left ventricular end diastolic
pressure. Work index (i.e. rate-pressure product, RPP) was cal-
culated as the product of LVDP and heart rate (HR). Time de-
rivatives of pressure measured during contraction (+dP/dt)
and relaxation (dP/dt) were computed using the software
Chart 5 (ADInstruments Ltd, Oxford, UK). Pre-ischaemic
values of the haemodynamic parameters were measured at
the end of the equilibration period prior to any pre-ischaemic
intervention. As the hearts in our experiments beat spontane-
ously, haemodynamic function is reﬂected in both LVDP and
HR. For this reason, RPPwas considered as themain parameter
characterizing haemodynamic function. If RPP was less than
15 000 mmHg·beat·min1 at the end of the pre-ischaemic
equilibration period, the heart was excluded from the exper-
iment. The absolute values of the haemodynamic indices are
shown in the Tables 1 and 2. For analysis of RPP response to
heart perfusion with the cAMP analogues and inhibitors, the
data were presented as percentage of pretreatment value
(Figure 2). This normalization was performed for clarity
and in order to avoid unwanted variations of the absolute
values.
Heart perfusion protocols
After a 25 min period of equilibration followed by pre-
ischaemic interventions, global normothermic ischaemia
(37°C) was induced for 30 min, and then normothermic
perfusion was reinstated for 2 h.
To investigate the cardioprotective effects of 8-Br against
I/R injury, hearts were randomly distributed between control
or interventions groups (six to seven hearts per group,
Figure 1). These hearts were treated with either 5 or 10 μM
8-Br for 5 min followed by 5 min washout immediately prior
to index ischaemia (Figure 1). We used 5 μM 8-Br for optimi-
zation and in our early experiments in Series 1. However, in
Series 2 performed 2 years later, the hearts were more vulner-
able to I/R injury compared with Series 1 as shown by higher
infarct size (70.1 ± 5.2% vs. 45.5 ± 5.7%, respectively;
P < 0.05, Figures 5B and 6B). As a result, 5 μM 8-Br produced
a relatively smaller cardioprotective effect. Therefore, the
dose was increased to 10 μM, which generated a comparable
marked protective effect (see Results). To test the effect of 8-
Br in the presence of an Epac inhibitor, hearts were perfused
with 1 μM ESI-09 for 5 min followed by 5 min perfusion with
5 μM 8-Br and 5 min washout. In an additional group of ex-
periments, PKA inhibitors, 10 μM of H-89 or 3 μM of PKI
(Glass et al., 1989), were present 5 min before, 5 min during
and 5 min after the heart perfusion with 8-Br. Control hearts
were perfused without drugs.
To investigate the effects of the PKA activator 6-Bnz and
the Epac activator CPT alone and in a combination, hearts
were randomly distributed between control or interventions
groups (ﬁve to six hearts per group, Figure 1). In the control
Table 1
Effects of 8-Br with or without ESI-09 (inhibitor of Epac), H-89 or PKI (inhibitors of PKA) and chelerythrine (Chel; inhibitor of PKC) on
haemodynamic function recovery during reperfusion
Parameters
LVDP
(mmHg)
HR
(beat·min1)
RPP
(mmHg·beat·
min1)·103
+dP·dt1
(mmHg·s1)·102
dP·dt1
(mmHg·s1)·102
Pre-ischaemic equilibration (n = 58) 64.8 ± 2.4 294.3 ± 5.4 19.1 ± 0.8 28.4 ± 1.1 20.3 ± 1.0
Reperfusion
Experimental Series 1
Control (n = 7) 19.0 ± 4.0*** 289.0 ± 21.8 5.5 ± 1.0*** 9.9 ± 1.1*** 9.6 ± 1.0***
8Br (5 μM, n = 7) 64.5 ± 7.6* 262.7 ± 10.5 17.3 ± 2.6* 23.2 ± 3.1* 16.0 ± 2.3*
8Br + ESI09 (n = 7) 23.3 ± 8.0** 231.1 ± 13.0* 5.4 ± 1.9** 8.7 ± 2.2** 7.9 ± 1.6**
8Br + H89 (n = 6) 26.1 ± 4.9** *** 202.8 ± 25.5* 5.0 ± 1.3** 10.0 ± 1.6** 8.5 ± 1.2**
ESI09 (n = 7) 19.2 ± 4.0** *** 264 ± 10.8 5.1 ± 1.1** *** 8.7 ± 1.4** *** 8.8 ± 1.4** ***
Experimental series 2
Control (n = 7) 32.5 ± 6.7*** 300.4 ± 5.5 8.6 ± 1.3*** 13.7 ± 2.6*** 12.2 ± 2.4***
8Br (10 μM, n = 7) 97.4 ± 9.1* *** 245.4 ± 11.6* 23.7 ± 2.7* 34.2 ± 3.8* 23.9 ± 2.3*
8Br + Chel (n = 5) 102.9 ± 7.4* 228.2 ± 14.9* 23.4 ± 2.1* 39.6 ± 3.2* 26.9 ± 2.4*
8Br + PKI (n = 5) 57.8 ± 7.1* 294.0 ± 11.4 17.1 ± 2.4* 24.4 ± 3.4* 20.2 ± 2.4*
PKI (n = 5) 37.2 ± 9.2** *** 294.2 ± 37.9 7.5 ± 2.6** *** 15.4 ± 4.0** *** 14.4 ± 3.2***
Haemodynamic function was recorded throughout the experimental protocol. The data shown are for the end of the equilibration period prior to
ischaemia and after 60 min reperfusion. Pre-ischaemic data are shown as average of all the hearts of this series of experiments.
*P < 0.05 signiﬁcantly different from control; **P < 0.05 signiﬁcantly different from 8-Br of the corresponding experimental series; ***P < 0.05 signif-
icantly different from initial (end of equilibration) value of the same group of hearts.
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group, hearts were perfused for 35 min with no intervention
prior to ischaemia. Three other groups of hearts were perfused
with either the PKA activator 6-Bnz (10 μM), the Epac activa-
tor CPT (10 μM) or the mixture of these two cAMP analogues
(Figure 1). These cAMP analogues were perfused for 5 min
followed by 5 min washout.
Additional hearts (six hearts per group) with or without
treatment with 8-Br, 6-Bnz or CPT were also collected, frozen
in liquid nitrogen at the end of the pre-ischaemic protocol
and used to determine PKCδ and PKCε translocation from
the cytosol to membrane fraction, VASP phosphorylation or
PKA activity.
To investigate the involvement of PKC in mediating the
effects associated with PKA and Epac activation by 8-Br
(Christensen et al., 2003), hearts were randomly divided into
a control group, a 8-Br group and a 8-Br + chelerythrine group
(ﬁve hearts per group, Figure 1). In the control group, the
hearts were perfused for 40 min with no intervention prior
to ischaemia. In the other two groups, hearts were perfused
with 8-Br (10 μM) for 5 min in the absence or presence of the
non-selective PKC inhibitor, chelerythrine (10 μM) according
to the protocol similar to that with the PKA inhibitors.
Analysis of haemodynamic function recovery, LDH re-
lease during reperfusion and infarct size, was performed in
all hearts subjected to I/R.
The speciﬁc Epac inhibitory activity of ESI-09 was con-
ﬁrmed previously (Chen et al., 2013). Rehmann H et al.
(2013) found that ESI-09 have general protein denaturing
properties. However, a recent study (Zhu et al., 2015) has re-
vealed that ESI-09 inhibits Epac activity with apparent IC50
values well below the concentrations (over 25 μM) shown to
induce its effect on protein folding.
Previously, we have shown on a similar model of I/R that
H-89 or chelerythrine alone at the concentration of 10 μM
had no effect on I/R injury (Khaliulin et al., 2007; Khaliulin
et al., 2010). For this reason, the groups of hearts with H-89
or chelerythrine alone were not included in this study.
Cardiac injury
LDH activity in the efﬂuent perfusate collected from the
hearts of all groups prior to ischaemia and during each
5 min over the ﬁrst 30 min of reperfusion was determined as
described previously (Bergmeyer and Bernt, 1963; Khaliulin
et al., 2014). Infarct size was determined as described else-
where (Pasdois et al., 2007). Brieﬂy, at the end of reperfusion,
hearts were stained with 1% of triphenyltetrazolium chlo-
ride, frozen at 20°C, sliced into six slices and immersed in
4% formaldehyde. Images of the heart slices were obtained
using an HP scanner, and the necrotic and intact areas of each
side for each of the heart slices were determined using
Table 2
Effects of 6-Bnz and CPT on haemodynamic function recovery during reperfusion
Parameters
LVDP
(mmHg)
HR
(beat·min1)
RPP
(mmHg·beat·
min1)·103
+dP·dt1
(mmHg·s1)·102
dP·dt1
(mmHg·s1)·102
Pre-ischaemic equilibration (n = 23) 77.6 ± 5.1 277.2 ± 6.1 21.4 ± 1.4 30.7 ± 1.5 20.4 ± 1.1
Reperfusion
Control (n = 7) 30.1 ± 5.9 228.6 ± 39.5 6.9 ± 1.2 12.0 ± 1.6 10.3 ± 0.9
6Bnz (n = 5) 23.6 ± 4.2** 240.8 ± 30.4 6.0 ± 1.4** 11.2 ± 1.5** 9.5 ± 1.4**
CPT (n = 5) 30.9 ± 9.9** 248.2 ± 27.5 7.1 ± 2.3** 11.9 ± 2.3** 10.4 ± 1.5**
6Bnz + CPT (n = 6) 66.2 ± 10.8* 243.2 ± 7.5 16.1 ± 2.7* 22.1 ± 3.9* 17.1 ± 2.3*
Haemodynamic function was recorded throughout the experimental protocol. The data shown are for the end of the equilibration period prior to
ischaemia and after 60 min reperfusion. Pre-ischaemic data are shown as average off all the hearts of this series of experiments.
*P < 0.05, signiﬁcantly different from control; **P < 0.05, signiﬁcantly different from 6-Bnz + CPT.
Figure 1
Outline of the experimental protocols. Experimental Series 1. Hearts
were perfused with an activator of both PKA and Epac (8-Br, 5 μM),
an inhibitor of PKA (H-89) and Epac (ESI-09). Groups of hearts: Con-
trol, 8-Br, 8-Br + H-89 and 8-Br + ESI-09. Experimental Series 2. Hearts
were perfused with 8-Br (10 μM), a PKC inhibitor chelerythrine
(Chel) and a speciﬁc PKA inhibitor peptide PKI. Groups of hearts:
Control, 8-Br, 8-Br + PKI and 8-Br + Chel. Experimental Series 3.Hearts
were perfused with a PKA activator (6-Bnz) and an Epac activator
(CPT). Groups of hearts: Control, 6-Bnz, CPT and 6-Bnz + CPT.
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AlphaEase v5.5 software. The total necrotic and intact area of
ventricular myocardium for each heart was calculated. As the
entire heart was at risk from global ischaemia, the infarct size
was expressed by dividing the sum of necrotic areas by the
sum of total slice areas of the six slices to obtain the percent-
age of necrosis. Infarct size (Figures 5B, 6B and 7C) is
expressed as percentage of the whole heart area in order to
avoid unwanted variations of the absolute values.
Data and statistical analysis
The data and statistical analysis in this study comply with the
recommendations on experimental design and analysis in
pharmacology (Curtis et al., 2015). Data are presented as
mean ± SEM. The assignment of hearts to different groups
was randomized. The raw data were assessed independently
by two co-authors to ensure the correctness of conclusions.
Blinding was not used since all the measurements were not
subjective but strictly quantitative data. To detect a 25%
change at a power 0.8 and α = 0.05 with 8% SD, the effect size
required a minimum n = 5 animals per group as calculated by
the GPOWER programme. The statistical analysis was per-
formed using the software SPSS Statistics, Version 23 (IBM).
Statistically signiﬁcant differences in the LDH activity, hae-
modynamic function during reperfusion, infarct size, protein
expression in Western blots and the PKA kinase activity be-
tween the groups were evaluated by one-way ANOVA
followed by Fisher’s LSD multiple comparison post hoc test.
Pre-ischaemic parameters of haemodynamic function and
changes of the haemodynamic parameters during reperfu-
sion compared with the pre-ischaemic values were assessed
by one-way ANOVAwith repeatedmeasures followed by Fish-
er’s LSD test. The limit of statistical signiﬁcance was P < 0.05.
The post hoc tests were performed if F-test of variance had
achieved the necessary level of statistical signiﬁcance.
Materials
The cell-permeable cAMP analogues: 8-Br (8-bromoade-
nosine-30,50-cyclic monophosphate, acetoxymethyl ester);
6-Bnz (N6-benzoyladenosine-30,50-cyclic monophosphate,
acetoxymethyl ester; CPT (8-(4-chlorophenylthio)-20-O-
methyladenosine-30,50-cyclic monophosphate, acetoxymethyl
ester); and the Epac inhibitor, ESI-09 (3-[5-(tert.-butyl)isoxazol-
3-yl]-2-[2-(3-chlorophenyl)hydrazono]-3-oxopropanenitrile)
(Almahariq et al., 2013) were purchased from BioLog Life
Science Institute (Bremen, Germany). The PKA inhibitor
14–22 amide (PKI), cell-permeable, myristoylated was
purchased from Merck Millipore (Watford, UK). Other
biochemicals were purchased from Sigma (Gillingham, UK),
including the PKA inhibitor H-89 and the PKC inhibitor
chelerythrine. General chemicals were purchased from
Fischer Scientiﬁc (Loughborough, UK) or VWR-Jencons
(Lutterworth, UK).
Results
Optimization and validation of the effects of
cAMP analogues and inhibitors
The indirect (using isoprenaline) or direct (using 8-Br) activa-
tion of PKA and Epac caused a signiﬁcant increase in the
amplitude of Ca2+ transients measured in electrically stimu-
lated and superfused cardiomyocytes (Supplementary Infor-
mation Fig. S1). Interestingly, 5 μM 8-Br (activator of both
PKA and Epac) increased Ca2+ transients to the same extent
as the β-adrenoceptor agonist isoprenaline (10 nM). We have
previously shown that this concentration of isoprenaline,
in combination with adenosine, produced a powerful
cardioprotective effect (Khaliulin et al., 2014). Consequently,
5 μM 8-Br concentration was chosen for the Experimental
Series 1, when this compound was used in combination with
the PKA inhibitor, H-89 or the Epac inhibitor, ESI-09.
As cAMP is known to activate Epac, in addition to PKA,
we studied the role of Epac in mediating cardioprotection.
Experiments with H9C2 cells showed that 5 μM 8-Br
(non-selective activator of PKA and Epac) and 10 μM CPT
(selective activator of Epac) increased mRNA expression of
the Epac-target gene, c-fos, by 32 and 24-fold respectively
(Supplementary Information Fig. S2a) indicating similar
activation of Epac by these two cAMP analogues. The
8-Br-induced c-fos expression was completely blocked by
the Epac inhibitor ESI-09 (1 μM), consistent with Epac-
dependent regulation.
Phosphorylation of the PKA substrate VASP, on Ser157,
was used to compare PKA activation induced by 8-Br and
6-Bnz. Stimulation with 5 μM 8-Br was found to evoke a sim-
ilar level of VASP phosphorylation as 10 μM of the selective
PKA activator, 6-Bnz (Supplementary Information Fig. S2b).
We measured PKA activity in hearts treated with 6-Bnz
and CPT (Supplementary Information Fig. S3). Treating
hearts with CPT did not alter PKA activity. This was consistent
with published data indicating speciﬁcity of this Epac activa-
tor (Chen et al., 2013; Zhu et al., 2015). In contrast, PKA acti-
vation by 6-Bnz was evident in these experiments. These data
conﬁrm the selectivity of 6-Bnz for PKA and inability of the
Epac agonist CPT (10 μM) to activate PKA.
Our experiments show that 5 μM 8-Br induced a similar
level of PKA activation as 10 μM 6-Bnz, which matched the
PKA activation induced by 10 nM Iso used in our earlier study
(Khaliulin et al., 2014). 8-Br at a concentration of 5 μM also
induced Epac activation to a similar extent as 10 μM CPT.
We therefore used these concentrations of the three
different activators for evaluation of functional activity in
Langendorff-perfused hearts.
Pre-ischaemic haemodynamic effects of cAMP
analogues
Effects of simultaneous activation of PKA and Epac by
8-Br. Perfusion of hearts with 5 μM 8-Br resulted in a
marked increase in RPP, almost 250% of the pretreatment
value, by the end of the 5 min perfusion. Switching the
perfusion to normal KH (washout) reversed the changes in
RPP back to the initial value, by the end of the washout
period (Figure 2A). The increased haemodynamic function
induced by 8-Br was a result of increased LVDP since no
signiﬁcant change in HR was observed. When hearts were
perfused with 10 μM 8-Br, the changes in RPP were
similar to those treated with 5 μM 8-Br (Figure 2B). ESI-09
(1 μM), H-89 (10 μM) and PKI (3 μM) inhibited, to almost
the same extent, the positive inotropic effect of 8-Br
(Figure 2A–B).
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Effects of PKA and/or Epac activation using 6-Bnz and
CPT. Perfusion of isolated hearts for 5 min, with 10 μM 6-
Bnz brought about a slow LVDP-related increase in RPP
(Figure 2C). This effect reached a maximum during the
washout period. CPT alone (10 μM) also induced a positive
inotropic effect with a rise in RPP at the end of the 5 min
perfusion with the compound. This was signiﬁcantly lower
than in 8-Br-treated hearts at the same time point of the
experiment (P < 0.05). Interestingly, the positive inotropic
effect of CPT was readily reversible with washing. Perfusion
of hearts with the mixture of 10 μM 6-Bnz and 10 μM CPT
led to a very sharp rise in RPP which was twofold higher
than in hearts treated with either 6-Bnz or CPT alone, at the
end of the 5 min perfusion (Figure 2C).
The effect of heart perfusion with 8-Br on
activation of PKCδ and PKCε
Perfusion of hearts with 5 μM 8-Br had no effect on PKCδ
translocation (activation) from the cytosol to the membrane
fraction (Figure 3A). However, there was a signiﬁcant increase
in PKCε activation as shown by a nearly threefold increase in
the membrane-to-cytosol ratio, as assessed by optical density,
in 8-Br-treated hearts (Figure 3B). Equal protein loading was
conﬁrmed by Ponceau-S staining (Supplementary Informa-
tion Fig. S4)
The cardioprotective effect of simultaneous
activation of PKA and Epac using 8-Br
Hearts were perfused with 5 μM 8-Br for 5 min with or with-
out an Epac inhibitor ESI-09 or PKA inhibitors H-89 and PKI
(see the Methods for details). The drugs were washed out for
5 min before inducing a 30 min global ischaemia followed
by 2 h reperfusion.
Recovery of haemodynamic function. Recovery of haemodynamic
function during reperfusion in the control hearts, in hearts
treated with 8-Br (with or without ESI-09, H-89 and PKI)
and in hearts perfused with ESI-09 or PKI alone is
presented in Table 1 and Figure 4. There was poor
functional recovery in the control, untreated hearts, as
measured by the developmental rate of contraction (+dP/
dt) and relaxation (dP/dt) and LVDP. These indices
recovered to less than 50% of the corresponding pre-
ischaemic values. The RPP at the end of 1 h reperfusion
was markedly lower compared with the baseline (Table 1,
Figure 4). This effect was largely due to changes in LVDP
as there was no signiﬁcant change in computed HR.
Pretreatment with either ESI-09 (1 μM) or PKI (3 μM) did
not affect the functional recovery. Pretreatment of hearts
with 5 μM 8-Br prior to ischaemia markedly improved
functional recovery during reperfusion with +dP/dt, LVDP
and RPP showing recovery to >90% of the pre-ischaemic
values (Table 1, Figure 4A). In hearts pretreated with
10 μM 8-Br, there was also a full recovery of RPP (Table 1,
Figure 4B). The improved functional recovery in hearts
treated with 8-Br was prevented by the pretreatment with
either a PKA inhibitor (10 μM H-89) or Epac inhibitor
(1 μM ESI-09) (Table 1, Figure 4A). This was also
conﬁrmed using a selective PKA inhibitor peptide PKI,
Figure 2
The effect of cAMP analogues on RPP of rat isolated
Langendorff-perfused hearts. The data are presented as percentage
of pretreatment values calculated for each heart. Panel A – Changes
in RPP induced by heart perfusion with 8-Br (5 μM) alone or in the
presence of 1 μM ESI-09 or 10 μM H-89. Groups of hearts: 8-Br,
n = 7; 8-Br + ESI-09, n = 7; 8-Br + H-89, n = 6. *P < 0.05, signiﬁcant
effect of inhibitor (H-89 or ESI-09). Panel B – Changes of RPP induced
by heart perfusion with 8-Br (10 μM) alone or in the presence of 3 μM
PKI. Groups of hearts: 8-Br, n = 7; PKI, n = 5; 8-Br + PKI, n = 5. Panel C
– Changes of RPP induced by the heart perfusion with 6-Bnz (10 μM)
and CPT (10 μM) alone or in combination. Groups of hearts: 6-Bnz,
n = 5; CPT, n = 5; 6-Bnz + CPT, n = 6. *P< 0.05, signiﬁcantly different
from the combination of 6-Bnz and CPT.
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which partly reduced 8-Br-induced improvement of the
recovery of haemodynamic function (Table 1, Figure 4B).
Cardiac injury. The excellent recovery in cardiac function
following I/R in hearts pretreated with 8-Br was also
associated with a signiﬁcant decrease in cardiac injury as
measured by LDH release and infarct size (Figures 5 and 6).
8-Br reduced LDH activity by threefold and infarct size by
3.5-fold. Consistent with effects on functional recovery,
both ESI-09 and H-89 abolished (Figure 5), and PKI
inhibited this effect (Figure 6). This was manifested through
increased LDH activity and infarct size during reperfusion.
Neither ESI-09 nor PKI alone had any effect on LDH release
or infarct size during reperfusion.
Figure 3
The effect of 8-Br on translocation of PKCδ and PKCε from the cytosol
to membrane fraction. PKC translocation, reﬂecting its activation,
was assessed by Western blots and expressed as a ratio of the optical
density of the membrane-to-cytosol fraction. Groups of hearts: con-
trol, n = 6; 8-Br, n = 6. Panel A – 8-Br (5 μM) had no effect on PKCδ
translocation. Panel B – 8-Br (5 μM) promoted PKCε translocation.
*P < 0.05, signiﬁcantly different from control.
Figure 4
The effect of 8-Br with or without ESI-09, H-89 and PKI on RPP recov-
ery after I/R. For clarity, RPP is expressed as percentage of the initial
value measured at the end of equilibration period prior to any inter-
vention. Panel A – Groups of hearts: Control, n = 7; 8-Br, n = 7; ESI-
09, n = 7; 8-Br + ESI-09, n = 7; 8-Br + H-89, n = 6. Pretreatment of
hearts with 8-Br (5 μM) fully restored RPP after 30 min global ischae-
mia and 60 min reperfusion, but ESI-09 (1 μM) and H-89 (10 μM)
abolished this effect. Perfusion of hearts with ESI-09 alone had no ef-
fect on the RPP recovery. Panel B – Groups of hearts: Control, n = 7;
8-Br, n = 7; PKI, n = 5; 8-Br + PKI, n = 5. Pretreatment of hearts with 8-
Br (10 μM, n = 7) fully restored RPP, but PKI (3 μM, n = 5) inhibited
this effect. Perfusion of hearts with PKI alone had no effect on the
RPP recovery. *P < 0.05, signiﬁcantly different from control;
#P < 0.05, signiﬁcantly different from 8-Br.
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The cardioprotective effects of activating either
PKA or Epac
In these experiments, hearts were perfused with either 6-Bnz
or CPT prior to I/R to investigate the effect of PKA and Epac
activation respectively.
Recovery of haemodynamic function. Post-ischaemic recovery
of haemodynamic function in control hearts and in hearts
pretreated with the selective PKA activator 6-Bnz and the
Epac speciﬁc activator CPT is presented in Figure 7A and
Table 2. Neither perfusion of hearts with 10 μM 6-Bnz
nor with 10 μM CPT alone improved recovery of
haemodynamic parameters during reperfusion, compared
with the control values. However, pre-ischaemic perfusion
of hearts with the mixture of these two cAMP analogues
Figure 5
The effect of 8-Br with or without ESI-09 and H-89 on cardiac injury
following I/R. Groups of hearts: Control, n = 7; 8-Br, n = 7; ESI-09,
n = 7; 8-Br + ESI-09, n = 7; 8-Br + H-89, n = 6. Panel A – Activity of
LDH in the efﬂuent perfusate was reduced by pretreatment of hearts
with 8-Br (5 μM), but ESI-09 (1 μM) and H-89 (10 μM) abolished this
effect. Insert – Mean area under the curve reﬂecting the total release
of LDH. The column-ﬁlls in the insert correspond to the column-ﬁlls
in Panel B. Panel B – Infarct size was calculated as percentage of the
whole heart area. Infarct size during reperfusion was reduced by
pretreatment of hearts with 8-Br (5 μM), but ESI-09 (1 μM) and
H-89 (10 μM) abolished this effect. ESI-09 alone had no effect on
cardiac injury. Representative heart slices with infarcted myocardium
(pale white area) are shown under the corresponding columns.
*P < 0.05, signiﬁcantly different from control.
Figure 6
The effect of 8-Br with or without PKI on cardiac injury following I/R.
Groups of hearts: Control, n = 7; 8-Br, n = 7; PKI, n = 5; 8-Br + PKI,
n = 5. Panel A – LDH activity in the efﬂuent perfusate was reduced
by pretreatment of hearts with 8-Br (10 μM) during reperfusion,
but PKI (3 μM) inhibited this effect. Insert – Mean area under the
curve reﬂecting the total release of LDH. The column-ﬁlls in the insert
correspond to the column-ﬁlls in Panel B. Panel B – Infarct size was
calculated as percentage of the whole heart area. Infarct size was sig-
niﬁcantly reduced by 8-Br (10 μM), but PKI (3 μM) inhibited this ef-
fect. PKI alone had no effect on cardiac injury. Representative heart
slices with infarcted myocardium (pale white area) are shown under
the corresponding columns. *P < 0.05, signiﬁcantly different from
control (n = 7); # P < 0.05, signiﬁcantly different from 8-Br.
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resulted in a complete recovery of +dP/dt, dP/dt, LVDP
and RPP.
Cardiac injury. As shown in Figure 7B, pretreatment of
hearts with CPT had no effect on LDH activity in the
efﬂuent collected during reperfusion. Meanwhile, 6-Bnz
transiently reduced LDH activity, which became signiﬁcant
compared with control after 15 min of reperfusion.
Perfusion of hearts with the mixture of 6-Bnz and CPT
resulted in a signiﬁcant reduction of LDH throughout
reperfusion (Figure 7B).
Although there was a trend for hearts pretreated with
6-Bnz to have a smaller infarct size compared with control,
this was not statistically signiﬁcant. Pretreatment with CPT
Figure 7
The effect of 6-Bnz or CPT on RPP recovery and cardiac injury following I/R. Groups of hearts: Control, n = 7; 6-Bnz + CPT, n = 6; CPT, n = 5; 6-Bnz,
n = 5. Panel A – RPP is expressed as percentage of the initial value measured at the end of equilibration period prior to any intervention. Neither
6-Bnz (10 μM) nor CPT (10 μM) had any effect on RPP recovery after 30 min ischaemia and 60 min of reperfusion, but the mixture of 6-Bnz and
CPT signiﬁcantly improved the recovery. Panel B – LDH activity in the efﬂuent perfusate was reduced by pretreatment of hearts with 6-Bnz (10 μM)
starting from 15 min of reperfusion; pretreatment of hearts with CPT (10 μM) had no effect, but the mixture of 6-Bnz and CPT signiﬁcantly
reduced LDH activity starting from the beginning of reperfusion. Insert – Mean area under the curve reﬂecting the total release of LDH. The
column-ﬁlls in the insert correspond to the column-ﬁlls in Panels A and C. Panel C – Infarct size was calculated as percentage of the whole heart
area. Neither 6-Bnz nor CPT alone reduced infarct size whilst the mixture of 6-Bnz and CPT signiﬁcantly reduced infarct size. Representative heart
slices with infarcted myocardium (pale white area) are shown under the corresponding columns. *P < 0.05, 6-Bnz + CPT signiﬁcantly different
from control; #P < 0.05, 6-Bnz signiﬁcantly different from control.
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did not affect infarct size. However, perfusion of hearts with
the mixture of 6-Bnz and CPT led to a signiﬁcant, nearly
twofold reduction of infarct size (Figure 7C).
The effect of PKC inhibition on cardioprotection
mediated by simultaneous activation of PKA
and Epac
In this set of experiments, hearts were perfused with 10 μM
8-Br for 5 min with or without the non-selective PKC
inhibitor, chelerythrine (10 μM).
Recovery of haemodynamic function. Functional recovery in
control hearts and in hearts treated with 8-Br, with or
without chelerythrine (Experimental series 2), is presented in
Table 1. The RPP in hearts pretreatedwith 8-Br reached a value
threefold higher than in the control group, after 1 h of
reperfusion. Addition of chelerythrine did not affect the
recovery of RPP in the 8-Br-treated hearts. However, recovery
of -dP/dt in hearts perfused with chelerythrine and 8-Br was
signiﬁcantly less than in the hearts perfused with 8-Br alone.
Cardiac injury. Pretreatment of hearts with 10 μM 8-Br
reduced LDH activity (Figure 8A) and infarct size by 4.5-fold
(Figure 8B) conﬁrming a strong protective effect. Adding
10 μM chelerythrine during the 8-Br pretreatment reduced
this effect.
Discussion
The availability of cell-permeable cAMP analogues that can
selectively activate either PKA or Epac or both has provided
a useful tool to study the contribution of PKA and Epac to
the cardioprotection against I/R injury. We have used these
analogues to demonstrate that optimal cardioprotection can
only be achieved by simultaneous activation of both en-
zymes. Our results also indicate that cardioprotection in-
duced by simultaneous activation of both PKA and Epac
using 8-Br is mediated, at least in part, by PKC.
In contrast to this study, earlier investigations of the
cardioprotective effects of cAMP were linked to activation of
adrenoceptors (Lochner et al., 1999; Khaliulin et al., 2010).
To the best of our knowledge, this is the ﬁrst report demon-
strating a β-adrenoceptor-independent cardioprotective ef-
fect of cAMP. This may provide a therapeutic advantage as
the sensitivity of β-adrenoceptors could be impaired in partic-
ular clinical settings (see Introduction).
Another interesting ﬁnding of this work is that activation
of either PKA or Epac using selective activators was sufﬁcient
to induce a clear inotropic effect in the perfused heart andwas
additive when these enzymes were activated simultaneously.
Therefore, the role of PKA and Epac activation in regulating
cardiac function and in cardioprotection is likely to be due
to parallel, mutually additive effects of PKA and Epac or due
to an interaction between these two signalling pathways.
Activation of both PKA and Epac is necessary
for maximal inotropic effect of cAMP
Perfusion of hearts with speciﬁc activators of either PKA or
Epac brought about an increase in cardiac pump function
(Figure 2). The positive inotropic effect of PKA is not
surprising (Bers, 2007). PKA has been shown to stimulate
excitation-contraction coupling by phosphorylating and
modulating activity of a variety of myocardial proteins,
including the L-type Ca2+ channel, ryanodine receptor
(RyR2), phospholamban, Ca2+/calmodulin-dependent pro-
tein kinase II (CaMKII), sarcoplasmic reticulum Ca2+ ATPase
Figure 8
The effect of 8-Br and chelerythrine (Chel) on cardiac injury follow-
ing I/R. Cardiac injury was assessed by measuring LDH activity and
infarct size. Groups of hearts: Control, n = 7; 8-Br, n = 7; 8-Br + Chel,
n = 5. Panel A – 8-Br (10 μM) reduced LDH activity in the efﬂuent
perfusate during reperfusion, but chelerythrine (10 μM) reversed
this effect. Panel B – 8-Br (10 μM) signiﬁcantly reduced infarct
size during reperfusion, but chelerythrine (10 μM) attenuated this
effect. *P < 0.05, signiﬁcantly different from control; #P < 0.05,
signiﬁcantly different from 8-Br.
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and troponin I, ensuring mobilization of energy resources,
up-regulation of Ca2+ cycling and increases in contractility
and lusitropy. However, the ﬁnding that Epac stimulates con-
traction was interesting as it was reported to mediate its ac-
tions independently of PKA pathways (Pereira et al., 2015).
Epac activation mediated by stimulation of β-adrenoceptors
has been linked to sarcoplasmic reticulum Ca2+ release. It
has been shown to activate CaMKII resulting in phosphoryla-
tion of RyR2 and phospholamban (Hothi et al., 2008;
Oestreich et al., 2009). An Epac-induced increase in contrac-
tility has also been shown in experiments on rat and mouse
cardiomyocytes (Metrich et al., 2010). The availability of
parallel Ca2+ regulatory pathways associated with Epac and
PKA, which independently trigger inotropic effects, may
explain the additive inotropic effect of the mixture of CPT
and 6-Bnz observed in our experiments.
Simultaneous activation of PKA and Epac
confers cardioprotection mediated by PKC
The cardiac effects associated with cAMP signalling depends
on a number of factors including but not limited to the dose,
timing and duration of intervention and the balance between
activation of PKA and Epac-related pathways. For example,
sustained stimulation of β-adrenoceptors can lead to
mitochondria-induced apoptosis, contractile dysfunction,
cardiac hypertrophy, arrhythmias, cell death and, eventually,
heart failure (Dorn et al., 2000; Appukuttan et al., 2012; Rau
et al., 2015).
In contrast to sustained β-adrenoceptor stimulation, a
moderate pre-ischaemic stimulation of the same receptors is
cardioprotective. Earlier data show that PKA activation in-
duced by stimulation of β-adrenoceptors, triggers an ischae-
mic preconditioning (IP)-like effect (Lochner et al., 1999)
and that repeated stimulation with noradrenaline or isopren-
aline mimics IP (Asimakis et al., 1994). Previously, we found
that temperature preconditioning induced by a few short-
term episodes of hypothermic and normothermic perfusion
(Khaliulin et al., 2007) is also mediated by PKA activation
(Khaliulin et al., 2010).
Consistent with a role of PKA in cardioprotection, the
PKA activator 6-Bnz signiﬁcantly reduced LDH activity in
the efﬂuent perfusate during reperfusion (Figure 7B). One
possible explanation for the cardioprotective effect of PKA ac-
tivation could be the fact that activation of this kinase by the
β-adrenoceptor agonist isoprenaline triggers glycogen deple-
tion (Khaliulin et al., 2010). This may result in reduced accu-
mulation of lactate, H+, Na+ and Ca2+ (Cross et al., 1996),
contributing to the cardioprotection observed (Halestrap
and Pasdois, 2009). A recent study has also linked the
depletion of myocardial glycogen prior to ischaemia to
cardioprotection via less dissociation of hexokinase II from
mitochondria, which results in MPTP inhibition (Pasdois
et al., 2013). The signalling pathways and targets that can
potentially be involved in the cardioprotective effect of PKA
may include the reduction of IKK/IκB phosphorylation
(Zhang et al., 2013), phosphorylation of GSK-3β (Gomez
et al., 2008; Juhaszova et al., 2004) and regulation of
phosphodiesterase (Omori and Kotera, 2007).
However, the protective effect of PKA activation in our
experiments was small and was not supported by a reduction
of infarct size (Figure 7C) or improvement in functional re-
covery (Table 2, Figure 7A). This ﬁnding does not appear to
be due to the extent of PKA activation by 6-Bnz as 8-Br, which
produces comparable activation of PKA (Supplementary In-
formation Fig. S2b), confers marked cardioprotection. This
clearly implies involvement of additional cAMP-sensitive
pathways, which may include Epac.
Consistent with the results reported by others
(Duquesnes et al., 2010) who used a similar model of I/R, per-
fusion of hearts with the Epac agonist CPT did not show a
clear protective effect. Nonetheless, we found that perfusion
of hearts with the mixture of the speciﬁc PKA activator
6-Bnz and the Epac activator CPT resulted in relatively very
high haemodynamic functional recovery (Figure 7A and
Table 2), signiﬁcantly reduced LDH release and infarct size
during reperfusion (Figure 7B–C). Similarly, 8-Br, which si-
multaneously activates PKA and Epac (Christensen et al.,
2003), markedly improved the recovery of haemodynamic
function (Table 1, Figure 4) and prevented I/R injury (Figures 5
and 6) implying that both PKA and Epac are involved during
cAMP-induced cardioprotection. This conclusion is also
supported by the fact that both PKA inhibitors (H-89 and
PKI) and the Epac inhibitor (ESI-09), which appeared to have
no effect on haemodynamic function recovery or I/R
injury by themselves [see (Khaliulin et al., 2010), Table 1 and
Figures 4–6], attenuated the cardioprotective effect of 8-Br.
Recent work using neonatal rat isolated cardiomyocytes
showed that stimulation of glucagon-like peptide-1 receptor
by exendin-4 mediated a cytoprotective effect, which was as-
sociated with both PKA and Epac-dependent pathways
(Mangmool et al., 2015). Our results, however, do not suggest
a simple additive cardioprotective effect of PKA and Epac but
a coordinated synergistic action of these two cAMP-related
pathways, particularly considering the absence of any protec-
tive effect of Epac activation alone and a relatively weak
cardioprotective effect of 6-Bnz-induced PKA activation.
Obviously, the Epac activation represents a necessary signal-
ling link that magniﬁes the protective effect of PKA through
mechanisms additional to PKA signalling pathways or by
enhancing the activation of pathways common to both PKA
and Epac. The latter is likely to include PKCε activation, as
we discuss below. A synergistic action has also been reported
in vascular smooth muscle cells where PKA and Epac
synergize to inhibit cell proliferation (Hewer et al., 2011).
Interestingly, our previous work demonstrated that
stimulation of β-adrenoceptors by isoprenaline only induced
a mild cardioprotective effect (Khaliulin et al., 2010). This
could be because PKA is more sensitive to cAMP than Epac
(Bos, 2003). However, when this was followed by PKC activa-
tion, the protection was marked (Khaliulin et al., 2010).
Importantly, our results demonstrate that PKC is also in-
volved in the 8-Br-induced cardioprotective effect since the
non-selective PKC inhibitor chelerythrine partly blocked
the effect of this cAMP analogue (Figure 8A–B, Table 1). 8-Br
promoted translocation of PKCε but not PKCδ from the cyto-
sol to membrane fraction of myocytes indicating a possible
role of PKCε in cAMP-induced cardioprotection. We have
previously identiﬁed PKC as a critical component of
cAMP-induced cardioprotection (Khaliulin et al., 2010). We
found that the PKA inhibitor H-89, which has little effect on
PKC activity (Bain et al., 2007), was able to prevent both
PKA and Epac activation and cardioprotection BJP
British Journal of Pharmacology (2017) 174 438–453 449
PKC activation induced by temperature preconditioning and
cardioprotection. These results imply that PKA activation
triggers PKC activation in the signalling pathway of tempera-
ture preconditioning (Khaliulin et al., 2010). In fact, the
cAMP-induced activation of PKCε may occur downstream to
both Epac and PKA activation. Cazorla et al. have shown that
Epac activates phospholipase C, which hydrolyzes phos-
phatidylinositol bisphosphate to produce diacylglycerol and
inositol triphosphate (IP3), leading to PKC activation or IP3
receptor-dependent Ca2+ release (Cazorla et al., 2009).
Furthermore, Li et al. have recently shown that the
β-adrenoceptor/Epac/PLC pathway may speciﬁcally activate
PKCε (Li et al., 2015). PKA, in turn, can activate PKC via
increased ROS production (Novalija et al., 2003) and [Ca2+]i
either by direct Ca2+-dependent activation or via a G-protein
activated by Ca2+-dependent phospholipase C (Dekker et al.,
1999). Hence, it is logical to suggest that PKCε may serve as
a connecting link between the PKA and Epac signalling
pathways in the cAMP-induced cardioprotection. This
hypothesis, however, requires further investigation.
Study limitations
Epac-mediated effects can be attributed to either Epac1 or
Epac2 or both. We did not study the role of the two isoforms
in our work but assessed the overall effect of Epac activation.
The two isoforms are believed to have different sub-cellular
localization, expression and function (Okumura et al.,
2014). This has been widely investigated within the mouse
heart (Schmidt et al., 2013). However, a recent study demon-
strated that both Epac isoforms are present within mitochon-
dria isolated from adult rat myocytes (Wang et al., 2016).
Current ﬁndings using rat hearts have implied that the
cardioprotective effect induced by urocortin-1 is mediated
by activation of Epac2 (Calderon-Sanchez et al., 2016) and
that Epac2 inhibition promotes cardiac arrhythmias (Yang
et al., 2016). Nonetheless, in the absence of direct evidence,
a role for the Epac1 isoform cannot be excluded. The genera-
tion and availability of selective Epac1 and Epac2 inhibitors
will provide tools to investigate the role of individual Epac
isoforms in the cardioprotective effect of cAMP in future
studies.
In conclusion, the results of our study, taken together,
demonstrated for the ﬁrst time that activation of either PKA
or Epac alone, prior to ischaemia, produced little or no
cardioprotection whereas simultaneous activation of both
enzymes conferred optimal and marked protection against
I/R injury. This effect was signiﬁcantly attenuated in the
presence of selective inhibitors of PKA and Epac. Activation
of PKA and Epac triggers PKC activation. Inhibition of PKC
can reduce the cardioprotective effect of cAMP implicating
PKC in the coordinated cardioprotective effect of simulta-
neous activation of PKA and Epac. The additive effect of
PKA and Epac activation is also manifested in their positive
inotropic effects.
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Figure S1 Isoprenaline (10 nM) and 8-Br (5 μM) increased
amplitude of Ca2+ transients in cardiomyocytes to a similar
extent. Groups of cells: Isoprenaline (Iso, n = 9); 8-Br (n = 7).
Panel A – Representative recording of Ca2+ transient in a car-
diomyocyte superfused with Iso for 5 min followed by
5 min washout. Panel B – Representative recording of Ca2+
transients in a cardiomyocyte superfused with 8-Br for
5 min followed by 5 min washout. Panel C – Value of increase
in the amplitude of Ca2+ transients in cardiomyocytes treated
with isoprenaline and 8-Br.
Figure S2 c-fos gene expression in H9C2 cells treated with
Epac activators and inhibitor (panel A) and comparison of
VASP phosphorylation by 8-Br and 6-Bnz (panel B). Panel A
– c-fos gene expression measured in H9C2 cells incubated
at 37°C for 7 h with either 5 μM 8-Br, 10 μM CPT or
5 μM 8-Br + 1 μM ESI-09. The gene expression was calcu-
lated as fold change relative to Control. The level of gene
expression in the control group was set as 1. Panel B – a
Western blot for phospho-VASP of the lysate of rat heart
treated with 8-Br (5 μM) and 6-Bnz (10–100 μM). Control – a
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lysate of untreated Langendorff-perfused rat heart. pVASP +
VE Control – a lysate of rat smooth muscle cells treated with
25 μM forskolin used as a positive control for PKA activation.
Figure S3 PKA activity in hearts perfused with 10 μM 6-Bnz
or 10 μM CPT. The hearts were freeze-clamped at the end of
the pre-ischaemic protocol, outlined in the Methods, and
powdered under liquid nitrogen. PKA activity was measured
using an ELISA-based PKA kinase activity assay kit (Abcam)
in 3 hearts of each of control, 6-Bnz and CPT groups. The
Table shows PKA activity (ΔOD·μg crude protein1) of each
heart.
Figure S4 PVDF membranes containing proteins of the
membrane and the cytosol fractions stained with Ponceau-S
for 2 min. The samples of control hearts and hearts treated
with 8-Br (n = 6 in each group) were alternated on the gel
and transferred on the membrane. The ﬁgure conﬁrms an
even loading of the proteins of different samples.
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